文献速递细菌感染、耐药与抗菌药物

德拉沙星治疗急性细菌性皮肤及皮肤结构感染:III期疗效数据汇总分析

Analysis of Pooled Phase III Efficacy Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections.
PubMed 文献 · Clin Infect Dis · 2019-01-01

该汇总分析纳入2项多中心随机双盲III期试验的1510例急性细菌性皮肤及皮肤结构感染成人患者,比较德拉沙星(静脉/口服)与万古霉素/氨曲南的疗效。结果显示德拉沙星在主要终点客观缓解率上非劣于对照方案(81.3% vs 80.7%,治疗差异0.8%,95%CI -3.2%至4.7),亚组及随访结果一致,耐受性相似。

要点

  • 德拉沙星单药(静脉/口服)治疗ABSSSI非劣于万古霉素/氨曲南联合方案。
  • 主要终点客观缓解率:德拉沙星81.3%,对照80.7%,治疗差异0.8%(95%CI -3.2%至4.7)。
  • MRSA清除率在随访时两组相当(98.1% vs 98.0%),不良事件频率相似。

核心结论

  • 静脉/口服德拉沙星固定剂量单药治疗在每项III期研究及汇总分析中均非劣于静脉万古霉素/氨曲南联合治疗,且耐受性良好,不受终点或分析人群影响。

研究设计与样本

  • 汇总2项多中心、随机、双盲III期试验,共1510例成人ABSSSI患者;万古霉素组每12小时接受15 mg/kg加1-2 g氨曲南,德拉沙星组研究302每12小时静脉300 mg,研究303静脉300 mg每12小时用3天后盲法转为口服450 mg每12小时。

主要发现

  • 意向治疗分析中,客观缓解率德拉沙星组81.3%,对照组80.7%,平均治疗差异0.8%(95%CI -3.2%至4.7)。
  • 研究者评估的成功率在随访(第14±1天)为84.7% vs 84.1%,晚期随访(第21-28天)为82.0% vs 81.7%。
  • 随访时MRSA清除率德拉沙星组98.1%,对照组98.0%;两组治疗中出现的不良事件频率相似。

关键数值与推荐

  • 主要终点客观缓解定义为原发感染部位红斑面积扩展在48至72小时(±2小时)内减少≥20%,且无临床失败。

临床怎么用

  • 对于ABSSSI成人患者,德拉沙星可作为万古霉素/氨曲南联合方案的替代选择,覆盖革兰阳性(包括MRSA)和革兰阴性菌。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Delafloxacin is an oral or intravenous (IV) antibiotic indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI), including both gram-positive (including methicillin-resistant Staphylococcus aureus [MRSA]) and gram-negative organisms. Chemically distinct from other quinolones, delafloxacin exhibits enhanced potency, particularly against gram-positive pathogens. The integration of efficacy data across the Phase III ABSSSI studies is presented here and allows for additional examination of results across subgroups. METHODS: Results of 2 multicenter, randomized, double-blind trials of 1510 adults with ABSSSI were pooled for this analysis. Subjects in the vancomycin arm received 15 mg/kg, plus 1-2 g of aztreonam every 12 hours. Delafloxacin was dosed at 300 mg IV every 12 hours in Study 302; dosing in Study 303 was 300 mg IV every 12 hours for 3 days, with a mandatory, blinded switch to delafloxacin at 450 mg orally every 12 hours. The primary endpoint was objective response (OR), defined as a ≥20% reduction of lesion spread of erythema area at the primary infection site at 48 to 72 hours (±2 hours), in the absence of clinical failure. Investigator-assessed response, based on the resolution of signs and symptoms at follow-up (FU; Day 14 ± 1) and late follow-up (LFU; Day 21- 28), were secondary endpoints. RESULTS: In the intent-to-treat analysis set, the OR was 81.3% in the delafloxacin arm and 80.7% in the comparator arm (mean treatment difference 0.8%, 95% confidence interval -3.2% to 4.7). Results for OR in the defined subgroups showed delafloxacin to be comparable to vancomycin/aztreonam. Investigator-assessed success was similar at FU (84.7% versus 84.1%) and LFU (82.0% versus 81.7%). Delafloxacin was comparable to vancomycin/aztreonam in the eradication of MRSA, at 98.1% versus 98.0%, respectively, at FU. The frequencies of treatment-emergent adverse events between the groups were similar. CONCLUSIONS: Overall, IV/oral delafloxacin fixed-dose monotherapy was non-inferior to IV vancomycin/aztreonam combination therapy and was well tolerated in each Phase III study, as well as in the pooled analysis, regardless of endpoint or analysis population.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Giordano PA, Pogue JM, Cammarata S, et al. Analysis of Pooled Phase III Efficacy Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections. Clin Infect Dis. 2019. PMID: 30957167. doi:10.1093/cid/ciz006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。